We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 03, 2021

Lenalidomide Plus R-CHOP vs Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type DLBCL

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
J. Clin. Oncol 2021 Feb 23;[EPub Ahead of Print], GS Nowakowski, A Chiappella, RD Gascoyne, DW Scott, Q Zhang, W Jurczak, M Özcan, X Hong, J Zhu, J Jin, D Belada, JM Bergua, F Piazza, H Mócikova, AL Molinari, DH Yoon, F Cavallo, M Tani, K Yamamoto, K Izutsu, K Kato, M Czuczman, S Hersey, A Kilcoyne, J Russo, K Hudak, J Zhang, S Wade, TE Witzig, U Vitolo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading